FDA clears Hologic’s Aptima SARS-CoV-2 assay
Hologic's Panther system, on which the assay runs, processes the samples, delivering initial outcomes in under three hours.
Opinion: Long COVID is solvable, but we need more clinical trials
Some people may remain ill after COVID infection because the virus still lurks in their bodies. The looming question now is: ...
Protection from COVID reinfections plummeted from 80% to 5% with omicron
With the rise of omicron came the fall of long-lasting protection from reinfection with the pandemic coronavirus SARS-CoV-2, ...
Pharmabiz6d
NanoViricides announces its antiviral drug, NV-387 can fight bird flu pandemic; H5N1 virus will not be able to escape even as it changes in the field
Shelton, Connecticut Thursday, February 13, 2025, 16:00 Hrs [IST] ...
Medscape35m
Vasculitis Patients Need Multiple COVID Vaccine Boosters
Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...
Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2?
Chitosan, a naturally occurring polysaccharide derived from chitin, has demonstrated significant potential as an antiviral ...
No, Moderna Did Not Create Its COVID Vaccine Two Years Before the Pandemic
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
pulmonologyadvisor6d
COVID Antiviral, mAb Treatments Reduce Mortality and Hospitalization Rates
Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.
Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay
(Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the ...